Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154775 | 0.77 | TSHR (0.34) | TSHRALDH1A1GAAKDM4EHPGD | |
| SCHEMBL11795168 | 0.77 | ALDH1A1 (0.42) | NPSR1TSHRALDH1A1GAAKDM4E | |
| SCHEMBL25072325 | 0.74 | DDB1 (0.34) | GAA | |
| SCHEMBL3623641 | 0.73 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL1478256 | 0.73 | SLC6A1 (0.46) | TSHRKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28790221 | 0.72 | SLC6A12 (0.44) | TSHRKDM4E | |
| SCHEMBL15011338 | 0.68 | POLB (0.41) | TSHRALDH1A1HSD17B10PKMSMN1; SMN2 | |
| SCHEMBL9199145 | 0.68 | — | — | |
| SCHEMBL27603777 | 0.67 | — | — | |
| SCHEMBL27741990 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6841562-B2 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | AVENTIS PHARMA S.A. (FR) | 2005-01-11 | — | — | US | disclosed |
| US-20040082610-A1 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | NOVEXEL (FR) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082610-A1 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | RRS1, MRPL21, FARSB | NPSR1 2953/4885TSHR 2967/4885ALDH1A1 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.